Comparative Effectiveness of Continuous Subcutaneous Insulin Infusion Using Insulin Analogs and Multiple Daily Injections in Pregnant Women with Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal of Women's Health

Volumn 24, Issue 3, 2015, Pages 237-249

  Ranasinghe, Padmini D ^a   Maruthur, Nisa M ^a   Nicholson, Wanda K ^c   Yeh, Hsin Chieh ^a,b   Brown, Todd ^a   Suh, Yong ^a   Wilson, Lisa M ^a   Nannes, Elisabeth B ^a   Berger, Zack ^a   Bass, Eric B ^a,b   Golden, Sherita Hill ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; PIG INSULIN; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

BIRTH WEIGHT; CESAREAN SECTION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DRUG SAFETY; FEMALE; FETUS DEATH; FETUS OUTCOME; FOLLOW UP; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; META ANALYSIS; NEWBORN DISEASE; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERINATAL MORTALITY; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STILLBIRTH; SYSTEMATIC REVIEW; WEIGHT GAIN; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY IN DIABETICS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY IN DIABETICS; TREATMENT OUTCOME;

EID: 84924693795     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2014.4939     Document Type: Review

References (26)

1. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991;265:731-736.
2. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 2008;31:1060-1079.
3. National Collaborating Centre for Women's and Children's Health (UK)Diabetes in pregnancy: Management of diabetes and its complications from preconception to the postnatal period. National Institute for Health and Clinical Excellence clinical guideline 63. London: RCOG Press, 2008 Available at: www.nice.org.uk/nicemedia/pdf/CG063Guidance.pdf Accessed November 1, 2014.
4. American Congress of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins. Clinical management guidelines for obstetrician-gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005;105:675-685.
5. Grunberger G, Bailey TS, Cohen AJ, et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract 2010;16:746-762.
6. Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007:CD005542.
7. Food and Drug Administration (FDA). Highlights of prescribing information: Levemire (insulin detemir [rDNA origin] injection) solution for subcutaneous injection. Silver Spring, MD: Health and Human Services, FDA, 2012. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2012/021536S039lbl.pdf Accessed November 1, 2014.
8. Golden SH, Brown T, Yeh HC, et al. Methods for insulin delivery and glucose monitoring. Comparative effectiveness reviews, No. 57. Rockville MD: Agency for Healthcare Research and Quality (US), 2012.
9. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-analysis. Ann Intern Med 2012;157:336-347.
10. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003;289:2254-2264.
11. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-S63.
12. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-384.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
15. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: Grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010;63:513-523.
16. Kernaghan D, Farrell T, Hammond P, Owen P. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol 2008;137:47-49.
17. Cypryk K, Kosinski M, Kaminska P, Kozdraj T, Lewinski A. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn 2008;118:339-344.
18. Volpe L, Pancani F, Aragona M, et al. Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. Gynecol Endocrinol 2010;26:193-196.
19. Bruttomesso D, Bonomo M, Costa S, et al. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab 2011;37:426-431.
20. Chico A, Saigi I, Garcia-Patterson A, et al. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: Influence of continuous subcutaneous insulin infusion and lispro insulin. Diabetes Technol Ther 2010;12:937-945.
21. Talaviya PA, Saboo BD, Joshi SR, et al. Pregnancy outcome and glycemic control in women with type 1 diabetes: A retrospective comparison between CSII and MDI treatment. Diabetes Metab Syndr 2013;7:68-71.
22. Wender-Ozegowska E, Zawiejska A, Ozegowska K, et al. Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for pregnant women with type 1 diabetes. Aust N Z J Obstet Gynaecol 2013;53:130-135.
23. Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007;197:447-456.
24. Ali S, Dornhorst A. Diabetes in pregnancy: Health risks and management. Postgrad Med J 2011;87:417-427.
25. Bush NC, Chandler-Laney PC, Rouse DJ, Granger WM, Oster RA, Gower BA. Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function. J Clin Endocrinol Metab 2011;96:E803-E809.
26. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.